Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
P2X Purinoceptor 3 (P2RX3) - Overview
P2X Purinoceptor 3 (P2RX3) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
P2X Purinoceptor 3 (P2RX3) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
P2X Purinoceptor 3 (P2RX3) - Companies Involved in Therapeutics Development
Bayer AG
Beijing Tide Pharmaceutical Co Ltd
Integral Molecular Inc
Merck & Co Inc
Neurim Pharmaceuticals Ltd
Ossianix Inc
Pfizer Inc
Shionogi & Co Ltd
P2X Purinoceptor 3 (P2RX3) - Drug Profiles
BAY-1817080 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BAY-1902607 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
gefapixant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclol Antibodies to Antagonize P2X3 Receptor for Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclol Antibody to Antagonize P2X2 and P2X3 for Visceral Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NEO-5937 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OSX-300 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OSX-300 Backups - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
piromelatine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
S-600918 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize P2X3 for Inflammatory Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize P2X3 Receptor for Chronic Pain and Neuropathic Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize P2X3 for Neuropathic Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TDI-06 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
P2X Purinoceptor 3 (P2RX3) - Dormant Products
P2X Purinoceptor 3 (P2RX3) - Discontinued Products
P2X Purinoceptor 3 (P2RX3) - Product Development Milestones
Featured News & Press Releases
Aug 26, 2019: BELLUS Health strengthens leadership team with appointment of Dr. Catherine Bonuccelli, MD as Chief Medical Officer
Jul 31, 2019: Bellus Health starts recruitment in Phase II chronic cough trial
Jul 25, 2019: Evotec SE: P2X3 antagonist demonstrates efficacy against refractory chronic cough in Phase II (POC)
Jul 25, 2019: Positive Phase II data for P2X3 antagonist in patients with refractory chronic cough
Jul 15, 2019: BELLUS Health convenes KOL meeting to discuss the state of chronic cough treatment
May 21, 2019: BELLUS Health presents Phase 1 data for BLU-5937, its lead product candidate for the treatment of refractory chronic cough, at the American Thoracic Society Intertiol Conference
May 15, 2019: BELLUS Health to present at three upcoming healthcare investor conferences
May 08, 2019: BELLUS Health provides update on its chronic cough drug candidate BLU-5937
Apr 04, 2019: BELLUS Health to Present at Two Upcoming Healthcare Investor Conferences
Apr 03, 2019: BELLUS Health announces clearance of U.S. IND for BLU-5937 phase 2 study in chronic cough patients
Dec 12, 2018: Altasciences Contributes to Positive Top-Line Phase 1 Results for Chronic Cough Drug Candidate
Nov 14, 2018: BELLUS Health updates BLU-5937 top-line phase 1 results timeline to November 2018
Oct 31, 2018: Bellus health announces issuance of new U.S. patent claiming P2X3 selectivity as a means of minimizing taste effects for its lead chronic cough drug candidate BLU-5937
Sep 25, 2018: BELLUS Health announces appointment of clinical advisory board
Jul 19, 2018: BELLUS Health Announces Patent Protection Secured in All Major Pharmaceutical Markets for Lead Drug Candidate BLU-5937
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019


List of Tables


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Bayer AG, H2 2019
Pipeline by Beijing Tide Pharmaceutical Co Ltd, H2 2019
Pipeline by Integral Molecular Inc, H2 2019
Pipeline by Merck & Co Inc, H2 2019
Pipeline by Neurim Pharmaceuticals Ltd, H2 2019
Pipeline by Ossianix Inc, H2 2019
Pipeline by Pfizer Inc, H2 2019
Pipeline by Shionogi & Co Ltd, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Discontinued Products, H2 2019